Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (150.000 €): Cohesin-Therapeutika. Präzisionsmedizin zur Behandlung von STAG2-mutierten Krebsarten Hor 01.06.2022 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Auf einen Blick

Text

Cohesin-Therapeutika. Präzisionsmedizin zur Behandlung von STAG2-mutierten Krebsarten

The cohesin gene STAG2 has emerged as a new tumour suppressor frequently mutated in bladder cancer, Ewing sarcoma and acute myeloid leukaemia (AML). Currently, these cancers are treated by cytotoxic therapies and surgery. These treatment plans are limited by unwanted side effects, have not been able to eliminate the high mortality caused by AML, and have not improved over the last few decades. STAG2 mutations are therefore a biomarker for cancer patients with high medical need. We discovered that STAG2 mutated cancer cells are highly vulnerable to the inactivation of another protein, called STAG1, while healthy cells remain unaffected. This highly selective sensitivity of cancer cells towards such a treatment is exceptional and could be exploited for precision medicine. Our long-term aim is therefore to develop STAG1 inhibitors. This precision medicine would greatly decrease side effects and costs, from which patients, doctors, and health insurance companies would benefit. To enable the development of such a STAG1 inhibitor, exploring the innovation potential is essential. For this, several stepping stones need to be reached which we would like to achieve with support of this ERC-PoC grant: (1) optimising our building blocks for a STAG1 inhibitor (2) developing an intellectual property strategy, (3) assessing commercial feasibility and (4) developing a business plan. Altogether, this will result in a proposition package that can be used to present the commercial potential to strategic partners. For this purpose, we have assembled a team that shares the same enthusiasm to achieve our common goal: to develop precision medicine for patients suffering from STAG2 mutated cancer.


Geförderte Unternehmen:

Firmenname Förderungssumme
Forschungsinstitut FUR Molekulare Pathologie GmbH 150.000 €

Quelle: https://cordis.europa.eu/project/id/101069277

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: Forschungsinstitut für molekulare Pathologie GmbH, Wien, Österreich.